Core Viewpoint - The company, Sinovac Biotech, is distributing a substantial cash dividend of $55 per share to its shareholders, which is significantly higher than its stock price of $6.47, indicating a potential shift in its financial strategy and shareholder relations [1][2]. Group 1: Dividend Distribution - Sinovac Biotech will pay a cash dividend of $55 per share, which is 8.5 times its stock price prior to suspension [2]. - The company plans to issue a second special cash dividend of $19 per share and is considering a third special cash dividend ranging from $20 to $50 per share [2]. - Sinovac has established a new dividend policy to regularly return cash to shareholders [2]. Group 2: Financial Performance - From 2015 to June 2020, Sinovac Biotech reported a total profit of $240 million, while in 2021, it achieved a net profit of $14.5 billion, with a net profit attributable to the parent company of $8.46 billion [2]. - The company has reported losses for both 2023 and the first half of 2024 [2]. Group 3: Shareholder Disputes - The company has been embroiled in a control battle since 2016, involving legal disputes over its management and ownership structure [2][3]. - A recent court ruling favored one faction led by Li Jiaqiang, but ongoing disputes continue, with claims of irresponsible actions by the current board under 1 Globe Capital LLC [4]. - The previous board's interests are represented by Weiwang Capital, which has initiated legal action against the current board, alleging that it prioritizes the interests of 1 Globe over other shareholders [4][5]. Group 4: Strategic Implications - The substantial dividend payments may be a strategy by the current controlling party to mitigate conflicts and reduce the perceived value of the company in the ongoing disputes [5].